ZA202207541B - Substituted triazinones as thyroid hormone receptor agonists - Google Patents
Substituted triazinones as thyroid hormone receptor agonistsInfo
- Publication number
- ZA202207541B ZA202207541B ZA2022/07541A ZA202207541A ZA202207541B ZA 202207541 B ZA202207541 B ZA 202207541B ZA 2022/07541 A ZA2022/07541 A ZA 2022/07541A ZA 202207541 A ZA202207541 A ZA 202207541A ZA 202207541 B ZA202207541 B ZA 202207541B
- Authority
- ZA
- South Africa
- Prior art keywords
- thyroid hormone
- receptor agonists
- hormone receptor
- substituted triazinones
- triazinones
- Prior art date
Links
- 229940127535 Thyroid Hormone Receptor Agonists Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000005495 thyroid hormone Substances 0.000 abstract 1
- 229940036555 thyroid hormone Drugs 0.000 abstract 1
- 108090000721 thyroid hormone receptors Proteins 0.000 abstract 1
- 102000004217 thyroid hormone receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020071741 | 2020-01-13 | ||
| CN2020107757 | 2020-08-07 | ||
| PCT/CN2021/071381 WO2021143706A1 (en) | 2020-01-13 | 2021-01-13 | Substituted triazinones as thyroid hormone receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202207541B true ZA202207541B (en) | 2024-12-18 |
Family
ID=74418122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/07541A ZA202207541B (en) | 2020-01-13 | 2022-07-07 | Substituted triazinones as thyroid hormone receptor agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11780825B2 (https=) |
| EP (1) | EP4090652A1 (https=) |
| JP (1) | JP7728265B2 (https=) |
| KR (1) | KR20220128383A (https=) |
| CN (1) | CN115244037B (https=) |
| AU (1) | AU2021208027B2 (https=) |
| IL (1) | IL294494A (https=) |
| MX (1) | MX2022008626A (https=) |
| WO (1) | WO2021143706A1 (https=) |
| ZA (1) | ZA202207541B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| EP4090652A1 (en) | 2020-01-13 | 2022-11-23 | Eccogene (Shanghai) Co., Ltd. | Substituted triazinones as thyroid hormone receptor agonists |
| JP7813730B2 (ja) | 2020-06-17 | 2026-02-13 | オートバーン セラピューティクス，インク． | 甲状腺様作用剤 |
| WO2021257851A1 (en) | 2020-06-17 | 2021-12-23 | Autobahn Therapeutics, Inc. | Thyromimetics |
| EP4240730A1 (en) | 2020-11-06 | 2023-09-13 | Aligos Therapeutics, Inc. | 2-pyridones as thyroid hormone receptor modulators |
| CN114685450A (zh) * | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| CN117624069A (zh) * | 2022-08-19 | 2024-03-01 | 凯思凯迪（上海）医药科技有限公司 | 一种多环类甲状腺激素β受体激动剂及其用途 |
| CN118146123A (zh) * | 2024-02-04 | 2024-06-07 | 河北鼎泰制药有限公司 | 一种盐酸安罗替尼中间体的合成方法 |
| WO2026067791A1 (en) * | 2024-09-30 | 2026-04-02 | Ascletis Pharma (China) Co., Limited | 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives as thr-beta agonist or modulators for the treatment of obesity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP1088819B1 (en) * | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | 6-azauracil derivatives as thyroid receptor ligands |
| DK1262177T3 (da) | 2001-05-31 | 2006-11-20 | Pfizer Prod Inc | Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner |
| PL1919878T3 (pl) | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| TWI534144B (zh) | 2009-04-20 | 2016-05-21 | 田邊三菱製藥股份有限公司 | 甲狀腺荷爾蒙β受體作動藥 |
| JP5847533B2 (ja) | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| EP4090652A1 (en) | 2020-01-13 | 2022-11-23 | Eccogene (Shanghai) Co., Ltd. | Substituted triazinones as thyroid hormone receptor agonists |
| JP7813730B2 (ja) * | 2020-06-17 | 2026-02-13 | オートバーン セラピューティクス，インク． | 甲状腺様作用剤 |
-
2021
- 2021-01-13 EP EP21702359.7A patent/EP4090652A1/en active Pending
- 2021-01-13 CN CN202180019696.0A patent/CN115244037B/zh active Active
- 2021-01-13 KR KR1020227027435A patent/KR20220128383A/ko active Pending
- 2021-01-13 AU AU2021208027A patent/AU2021208027B2/en active Active
- 2021-01-13 WO PCT/CN2021/071381 patent/WO2021143706A1/en not_active Ceased
- 2021-01-13 MX MX2022008626A patent/MX2022008626A/es unknown
- 2021-01-13 US US17/147,538 patent/US11780825B2/en active Active
- 2021-01-13 IL IL294494A patent/IL294494A/en unknown
- 2021-01-13 JP JP2022542655A patent/JP7728265B2/ja active Active
-
2022
- 2022-07-07 ZA ZA2022/07541A patent/ZA202207541B/en unknown
-
2023
- 2023-08-11 US US18/448,277 patent/US12291518B2/en active Active
-
2025
- 2025-03-03 US US19/068,129 patent/US20250320197A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023510835A (ja) | 2023-03-15 |
| EP4090652A1 (en) | 2022-11-23 |
| CA3164404A1 (en) | 2021-07-22 |
| US12291518B2 (en) | 2025-05-06 |
| JP7728265B2 (ja) | 2025-08-22 |
| US20240190846A1 (en) | 2024-06-13 |
| US20250320197A1 (en) | 2025-10-16 |
| AU2021208027A1 (en) | 2022-07-28 |
| US20210230146A1 (en) | 2021-07-29 |
| IL294494A (en) | 2022-09-01 |
| KR20220128383A (ko) | 2022-09-20 |
| WO2021143706A1 (en) | 2021-07-22 |
| CN115244037B (zh) | 2024-10-25 |
| AU2021208027B2 (en) | 2025-10-16 |
| US11780825B2 (en) | 2023-10-10 |
| CN115244037A (zh) | 2022-10-25 |
| MX2022008626A (es) | 2022-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202207541B (en) | Substituted triazinones as thyroid hormone receptor agonists | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| NZ799066A (en) | Glp-1r receptor agonist compound and use thereof | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
| MX2023012971A (es) | Agonistas del receptor de orexina y sus usos. | |
| KR930000117A (ko) | 이미다졸 화합물, 이의 제조방법 및 용도 | |
| MX2024015961A (es) | Compuesto de 3,4-dihidroquinolin-2 (1h)-ona | |
| ZA202002762B (en) | Benzimidazole derivatives and their uses | |
| PH12022550441A1 (en) | Azaheteroaryl compound and application thereof | |
| PH12021552004A1 (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| MY209296A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| MX2023015074A (es) | Agonistas de sulfonamidas del receptor de orexina y sus usos. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| AU2015204609B2 (en) | Novel functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| EP4670791A3 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| WO2022099060A3 (en) | Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists | |
| MX2024002892A (es) | Azalidos inmunomoduladores. | |
| TW200510395A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| TW200633710A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |